Biomaterials and bone remodeling: The physiologic process required for biologization of bone substitutes

European Journal of Trauma

Volumn 32, Issue 2, 2006, Pages 102-106

  Amling, Michael ^a   Schilling, Arndt F ^b   Pogoda, Pia ^b   Priemel, Matthias ^b   Rueger, Johannes M ^a  

^a University of Medical School Hamburg Eppendorf   (Germany)

^b NONE

Author keywords

Biointegration; Bone formation; Bone resorption; Remodeling

Indexed keywords

BIOMATERIAL; LEPTIN;

ADRENERGIC SYSTEM; AUTOCRINE EFFECT; BONE MASS; BONE PROSTHESIS; BONE REGENERATION; BONE REMODELING; BONE STRUCTURE; HUMAN; HYPOTHALAMUS FUNCTION; MOLECULAR DYNAMICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PARACRINE SIGNALING; REVIEW;

EID: 33746435874     PISSN: 14390590     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00068-006-6049-6     Document Type: Review

References (49)

1. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 1969;3:211-37.
2. Baron R, Ravesloot J-H, Neff L, et al. Cellular and molecular biology of the osteoclast. In: Noda M, ed. Cellular and molecular biology of bone. San Diego: Academic Press. 1993;445-95.
3. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;3:345-57.
4. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
5. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif Tissues Int 1981;33:349-51.
6. Reddi AH. Bone morphogenesis and modeling: soluble signals sculp osteosomes in solid state. Cell 1997;89:159-61.
7. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
8. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
9. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
10. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
11. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Com 1998;247:610-5.
12. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
13. Riggs BL, Melton LJ. Medical progress: involutional osteoporosis. N Engl J Med 1986;314:1676-84.
14. Potts JT, Jüppner H. Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism, and bone development: The proteins, the genes, the receptors. In: Avioli LV, Krane SM, eds. Metabolic bone diseases. San Diego: Academic Press, 1998:51-94.
15. Whyte MP. Skeletal disorders characterized by osteosclerosis or hyperostosis. In: Avioli LV, Krane SM, eds. Metabolic bone diseases. San Diego: Academic Press, 1998;697-738.
16. Felix R, Hofstetter W, Cecchini, MG. Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur J Endocrinol 1996;134:143-56.
17. Grigoriadis AE, Wang Z-Q, Cecchini MG, et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone formation. Science 1994;266:443-8.
18. Boyce BF, Yoneda T, Lowe C, et al. Requirement of pp6oc-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-7.
19. Amling M, Neff L, Priemel M, et al. Progressive osteopetrosis and development of odontomas in aging c-Src deficient mice. Bone 2000;27:603-10.
20. Corral DA, Amling M, Priemel M, et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci 1998;95:13835-40.
21. Cooper C, Melton III LJ. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J,eds. Osteoporosis; San Diego: Academic Press. 1996:419-34.
22. Amling M, Grote HJ, Posl M, et al. Polyostotic heterogeneity of the spine in osteoporosis. Quantitative analysis and three-dimensional morphology. Bone Mineral 1994;27:193-208.
23. Riggs B, Khosla S, Melton MJ. A unitary model for involutional osteoporosis: Estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73.
24. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993;8:567-73.
25. Tremollieres FA, Pouilles JM, Ribot C. Vertebral post-menopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993;77:683-6.
26. Ravn P, Cizza G, Bjarnason HH, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. J Bone Min Res 1999;14:1622-7.
27. Cornish J. Reid IR. Skeletal effects of amylin and related peptides. Endocrinologist 1999;9:183-9.
28. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996;87:377-89.
29. Friedman JM Halaas JL. Leptin and the regulation of the body weight in mammals. Nature 1998;395:763-70.
30. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
31. Chehab F, Lim M, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996;12:318-20.
32. Ahima RS, Dushay J, Flier SN, et al. Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 1997;99:391-5.
33. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250-2.
34. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263-71.
35. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-5.
36. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000;100:197-207.
37. Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140:1630-1638.
38. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998;12:3168-81.
39. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
40. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434(7032):514-20.
41. Fu L, Patel MS, Bradley A, et al. The molecular clock mediates leptin-regulated bone formation. Cell 2005;1225:803-15.
42. Schwarzman RJ. New treatments for reflex sympathetic dystrophy. N Engl J Med 2000;343:654-6.
43. Schwarzman RJ, McLellan TL. Reflex sympathetic dystrophy. A review. Arch Neurol 1987;44:555-61.
44. Karsenty G. The genetic transformation of bone biology. Genes Dev 1999;13:3037-51.
45. Karsenty G. The complexities of skeletal biology. Nature 2003;423:316-8.
46. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-55.
47. Schilling AF, Filke S, Brink S, et al. Osteoclasts and biomaterials. Eur J Trauma 2006 (this issue).
48. Grossterlinden L, Janssen A, Schmitz N, et al. Deleterious tissue reaction to an alkylene bis(dilactoyl)-methacrylate bone adhesive in long-term follow-up after screw augmentation in an ovine model. Biomaterials 2006 (in press).
49. Ignatius AA, Augat P, Hollstein E, et al. Biocompatibility and functionality of the degradable polymer alkylene bis(dilactoyl)-methacrylate for screw augmentation in vivo. J Biomed Mater Res B Appl Biomater 2005;75B1:128-36.